Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Cambridge Trust Co.

Cambridge Trust Co. lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,440 shares of the medical research company’s stock after selling 129 shares during the period. Cambridge Trust Co.’s holdings in Edwards Lifesciences were worth $110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of EW. Vanguard Group Inc. grew its position in Edwards Lifesciences by 0.6% during the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after buying an additional 325,808 shares during the period. Alliancebernstein L.P. increased its stake in shares of Edwards Lifesciences by 0.3% in the 2nd quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company’s stock valued at $1,934,919,000 after purchasing an additional 66,763 shares in the last quarter. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the period. Finally, Brown Advisory Inc. boosted its position in Edwards Lifesciences by 5.7% during the third quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after purchasing an additional 818,849 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Citigroup boosted their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Evercore ISI raised their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Mizuho lifted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Finally, Truist Financial raised their target price on Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Trading Down 0.6 %

Shares of EW opened at $85.94 on Friday. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm has a market capitalization of $51.73 billion, a P/E ratio of 37.37, a P/E/G ratio of 4.29 and a beta of 1.05. The firm has a 50-day moving average price of $90.15 and a 200 day moving average price of $78.31. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.64 EPS. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.